Kamada (KMDA) Non-Current Deferred Tax Liability (2018 - 2026)
Kamada (KMDA) posted quarterly Non-Current Deferred Tax Liability of $2.9 million for Q1 2026, up 39.06% year-on-year from $2.1 million in Q1 2025, and up 73.59% on a QoQ basis from $1.7 million in Q4 2025.
Kamada (KMDA) Non-Current Deferred Tax Liability (2018 - 2026) Analysis & Trends
Kamada (KMDA) has reported Non-Current Deferred Tax Liability for 6 consecutive years, with $2.9 million the latest figure, recorded in Q1 2026.
- Quarterly Non-Current Deferred Tax Liability rose 39.06% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (up 39.06% YoY) and the FY2025 annual result came in at $1.7 million, up 238.32% from the prior year.
- Non-Current Deferred Tax Liability grew to $2.9 million in Q1 2026 per KMDA's latest filing, from $1.7 million in the prior quarter.
- Over the last five years, Non-Current Deferred Tax Liability for KMDA reached as high as $2.9 million in Q1 2026 and fell as low as $488000.0 in Q4 2024.
- A 3-year average of $1.6 million and a median of $1.7 million in 2025 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2025 — Non-Current Deferred Tax Liability surged 238.32% — and 2026, when it surged 39.06%.
- Year by year, Non-Current Deferred Tax Liability stood at $488000.0 in 2024, then jumped by 238.32% to $1.7 million in 2025, then jumped by 73.59% to $2.9 million in 2026.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $2.9 million, $1.7 million, and $1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Kamada | 401.22 Mn | 328.07 Mn | 19.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.87 Mn |
| Mar 31, 2026 | 2.87 Mn |
| Dec 31, 2025 | 1.65 Mn |
| Dec 31, 2025 | 1.65 Mn |
| Sep 30, 2025 | 1.72 Mn |
| Sep 30, 2025 | 1.72 Mn |
| Jun 30, 2025 | 659,000.00 |
| Jun 30, 2025 | 659,000.00 |
| Mar 31, 2025 | 2.06 Mn |
| Mar 31, 2025 | 2.06 Mn |
| Dec 31, 2024 | 488,000.00 |
| Dec 31, 2024 | 488,000.00 |
| Sep 30, 2020 | 298,000.00 |
| Sep 30, 2020 | 298,000.00 |
| Jun 30, 2020 | 632,000.00 |
| Jun 30, 2020 | 632,000.00 |
| Mar 31, 2020 | 939,000.00 |
| Mar 31, 2020 | 939,000.00 |
| Dec 31, 2019 | 1.31 Mn |
| Dec 31, 2019 | 1.31 Mn |